We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

47 hedge funds and large institutions have $16.3M invested in Oramed Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less capital invested

Capital invested by funds: $16.6M → $16.3M (-$320K)

1.27% less ownership

Funds ownership: 19.03% → 17.75% (-1.3%)

10% less funds holding

Funds holding: 52 → 47 (-5)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

56% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 16

Holders
47
Holders Change
-5
Holders Change %
-9.62%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
4
Increased
7
Reduced
16
Closed
9
Calls
$284K
Puts
–
Net Calls
+$284K
Net Calls Change
+$262K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$193K
2
BCM
BML Capital Management
Indiana
+$138K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$56.9K
4
Mariner
Mariner
Kansas
+$22.2K
5
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services
Minnesota
+$11K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$456K
2
PLC
Peapod Lane Capital
New York
-$369K
3
Two Sigma Investments
Two Sigma Investments
New York
-$138K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$114K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$86.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$29.7K – – –
UBS Group
27
UBS Group
Switzerland
$28.8K -$50.3K -22,804 -64%
AS
28
Altshuler Shaham
Israel
$26.6K – – –
CAM
29
Close Asset Management
United Kingdom
$26K – – –
GJIA
30
Glass Jacobson Investment Advisors
Maryland
$23.7K – – –
Mariner
31
Mariner
Kansas
$22.7K +$22.2K +10,086 New
SPIA
32
Steward Partners Investment Advisory
New York
$19.9K – – –
Osaic Holdings
33
Osaic Holdings
Arizona
$9.71K -$512 -232 -5%
Raymond James Financial
34
Raymond James Financial
Florida
$8.05K +$7.89K +3,576 New
HNB
35
Huntington National Bank
Ohio
$6.75K – – –
MCM
36
MAI Capital Management
Ohio
$4.62K – – –
National Bank of Canada
37
National Bank of Canada
Quebec, Canada
$4.38K – – –
SS
38
SBI Securities
Japan
$3.68K – – –
Northwestern Mutual Wealth Management
39
Northwestern Mutual Wealth Management
Wisconsin
$3.54K – – –
ME
40
McIlrath & Eck
Washington
$2.25K – – –
NFSG
41
Newbridge Financial Services Group
Florida
$2.25K +$2.21K +1,000 New
IA
42
IFP Advisors
Florida
$1.13K – – –
Jones Financial Companies
43
Jones Financial Companies
Missouri
$1.07K – – –
GSWM
44
Golden State Wealth Management
California
$682 – – –
AF
45
Allworth Financial
California
$675 +$662 +300 New
BCMLT
46
Beacon Capital Management LLC (Tennessee)
Tennessee
$493 – – –
HFS
47
Hopwood Financial Services
Virginia
$450 – – –
Two Sigma Advisers
48
Two Sigma Advisers
New York
– -$456K -213,000 Closed
Two Sigma Investments
49
Two Sigma Investments
New York
– -$138K -64,418 Closed
SG Americas Securities
50
SG Americas Securities
New York
– -$50K -23,446 Closed
1
2
3

ORMP Hedge Fund Activity: Q2 2025 in Review

47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2025, worth a combined $16.3M — down 1.9% from $16.6M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ORMP and 4 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 7 added.

The largest buyer was Citadel Advisors, adding an estimated $193K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $456K sold.

  • 47 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2025, down from 52 in Q1 2025.
  • Funds reported $16.3M of Oramed Pharmaceuticals stock for Q2 2025, down 1.9% quarter-over-quarter.
  • 4 funds opened new Oramed Pharmaceuticals positions in Q2 2025 and 9 closed out, a net change of -5 holders.
  • The largest Oramed Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $193K added.
  • The largest Oramed Pharmaceuticals seller in Q2 2025 was Two Sigma Advisers, an estimated $456K sold.

Based on aggregated 13F filings for Q2 2025.